GlassScriptPhysician profile
Lauren E Modrall
NPI 1609612662
$665.21
in general payments reported to CMS, 2019-2025
17 companies · $459 in 2025
The $459 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $206 · 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $665.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $665.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $113.95 | 2024 | Impella |
| Novo Nordisk INC | $99.50 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $96.73 | 2025 | Zepbound, Mounjaro, Kisunla |
| Abbott Laboratories | $45.98 | 2025 | Freestyle Libre 3 |
| Aimmune Therapeutics, INC. | $41.81 | 2024-2025 | Zenpep |
| Merck Sharp & Dohme LLC | $36.54 | 2025 | Capvaxive, Gardasil 9 |
| Abbvie INC. | $33.49 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $30.61 | 2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $23.78 | 2025 | |
| Acadia Pharmaceuticals INC | $22.02 | 2024 | Nuplazid |
| Teva Pharmaceuticals USA, INC. | $21.06 | 2024 | Austedo Xr |
| Astrazeneca Pharmaceuticals LP | $20.69 | 2025 | Farxiga |
| Scpharmaceuticals INC. | $17.69 | 2025 | |
| Amgen INC. | $16.63 | 2025 | Otezla, Repatha |
| Axsome Therapeutics, INC. | $15.39 | 2025 | Auvelity |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $14.96 | 2025 | Shingrix |
| Exact Sciences Corporation | $14.38 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Modrall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.